196 related articles for article (PubMed ID: 22189997)
1. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.
Berruti A; Sperone P; Ferrero A; Germano A; Ardito A; Priola AM; De Francia S; Volante M; Daffara F; Generali D; Leboulleux S; Perotti P; Baudin E; Papotti M; Terzolo M
Eur J Endocrinol; 2012 Mar; 166(3):451-8. PubMed ID: 22189997
[TBL] [Abstract][Full Text] [Related]
2. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
Flaherty KT; Schiller J; Schuchter LM; Liu G; Tuveson DA; Redlinger M; Lathia C; Xia C; Petrenciuc O; Hingorani SR; Jacobetz MA; Van Belle PA; Elder D; Brose MS; Weber BL; Albertini MR; O'Dwyer PJ
Clin Cancer Res; 2008 Aug; 14(15):4836-42. PubMed ID: 18676756
[TBL] [Abstract][Full Text] [Related]
4. Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models.
Mariniello B; Rosato A; Zuccolotto G; Rubin B; Cicala MV; Finco I; Iacobone M; Frigo AC; Fassina A; Pezzani R; Mantero F
Endocr Relat Cancer; 2012 Aug; 19(4):527-39. PubMed ID: 22673336
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.
Sperone P; Ferrero A; Daffara F; Priola A; Zaggia B; Volante M; Santini D; Vincenzi B; Badalamenti G; Intrivici C; Del Buono S; De Francia S; Kalomirakis E; Ratti R; Angeli A; Dogliotti L; Papotti M; Terzolo M; Berruti A
Endocr Relat Cancer; 2010 Jun; 17(2):445-53. PubMed ID: 20410174
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
Gradishar WJ; Kaklamani V; Sahoo TP; Lokanatha D; Raina V; Bondarde S; Jain M; Ro SK; Lokker NA; Schwartzberg L
Eur J Cancer; 2013 Jan; 49(2):312-22. PubMed ID: 22954665
[TBL] [Abstract][Full Text] [Related]
8. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Pölcher M; Eckhardt M; Coch C; Wolfgarten M; Kübler K; Hartmann G; Kuhn W; Rudlowski C
Cancer Chemother Pharmacol; 2010 May; 66(1):203-7. PubMed ID: 20204367
[TBL] [Abstract][Full Text] [Related]
10. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
[TBL] [Abstract][Full Text] [Related]
11. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
Scagliotti G; Novello S; von Pawel J; Reck M; Pereira JR; Thomas M; Abrão Miziara JE; Balint B; De Marinis F; Keller A; Arén O; Csollak M; Albert I; Barrios CH; Grossi F; Krzakowski M; Cupit L; Cihon F; Dimatteo S; Hanna N
J Clin Oncol; 2010 Apr; 28(11):1835-42. PubMed ID: 20212250
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
[TBL] [Abstract][Full Text] [Related]
13. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.
Berruti A; Terzolo M; Sperone P; Pia A; Della Casa S; Gross DJ; Carnaghi C; Casali P; Porpiglia F; Mantero F; Reimondo G; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Sep; 12(3):657-66. PubMed ID: 16172198
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine.
Quinkler M; Hahner S; Wortmann S; Johanssen S; Adam P; Ritter C; Strasburger C; Allolio B; Fassnacht M
J Clin Endocrinol Metab; 2008 Jun; 93(6):2057-62. PubMed ID: 18334586
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
Habra MA; Stephen B; Campbell M; Hess K; Tapia C; Xu M; Rodon Ahnert J; Jimenez C; Lee JE; Perrier ND; Boraddus RR; Pant S; Subbiah V; Hong DS; Zarifa A; Fu S; Karp DD; Meric-Bernstam F; Naing A
J Immunother Cancer; 2019 Sep; 7(1):253. PubMed ID: 31533818
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
Murray A; Little SJ; Stanley P; Maraveyas A; Cawkwell L
Oncol Rep; 2010 Oct; 24(4):1049-58. PubMed ID: 20811688
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
Baselga J; Segalla JG; Roché H; Del Giglio A; Pinczowski H; Ciruelos EM; Filho SC; Gómez P; Van Eyll B; Bermejo B; Llombart A; Garicochea B; Durán MÁ; Hoff PM; Espié M; de Moraes AA; Ribeiro RA; Mathias C; Gil Gil M; Ojeda B; Morales J; Kwon Ro S; Li S; Costa F
J Clin Oncol; 2012 May; 30(13):1484-91. PubMed ID: 22412143
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.
Kroiss M; Quinkler M; Johanssen S; van Erp NP; Lankheet N; Pöllinger A; Laubner K; Strasburger CJ; Hahner S; Müller HH; Allolio B; Fassnacht M
J Clin Endocrinol Metab; 2012 Oct; 97(10):3495-503. PubMed ID: 22837187
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
Cheng AL; Kang YK; He AR; Lim HY; Ryoo BY; Hung CH; Sheen IS; Izumi N; Austin T; Wang Q; Greenberg J; Shiratori S; Beckman RA; Kudo M;
J Hepatol; 2015 Oct; 63(4):896-904. PubMed ID: 26071796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
